Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), as one of the most promising targeted drug for new cancer therapeutics, is limited in clinical application by the evolution of resistance in many cancer cell lines, especially in malignant melanoma. Thus, it is urgently needed to ident...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cao, Wenqiang, Li, Xiaoling, Zheng, Shanyuan, Zheng, Wenjie, Wong, Yum-shing, Chen, Tianfeng
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2014
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4202134/
https://ncbi.nlm.nih.gov/pubmed/25277183
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares